Apple Tree Partners

Apple Tree Partners is a New York-based venture capital firm founded in 1999, specializing in investments in biotechnology and life sciences companies across the United States. The firm collaborates with biopharmaceutical and medical device scientists and executives to create innovative, market-driven companies that address unmet medical needs. Apple Tree Partners primarily focuses on developing proprietary products and technologies, and while it prefers to initiate new companies, it is also involved with assets at various stages of development. The firm strategically leverages its investments through partnerships with larger venture firms, corporate collaborations, and unique financing methods to enhance growth potential within the pharmaceutical, biotechnology, oncology, and life science sectors.

Chris Cain

Associate, Therapeutics

Stephen G. Dance

CFO

Lauren Farrell

Chief Financial Officer

Sami Hamade

Partner, Medical Devices

David McIntyre

Partner, Medical Device

Stephanie Papes

Associate, Healthcare Services and Technology

Joshua Sherman

Associate, Medical Device

53 past transactions

Adendra Therapeutics

Series A in 2021
Adendra is an emerging biotechnology company building on new insights into dendritic cell biology to discover and develop new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases.
Developer of a focal non-viral gene therapy designed to overcome the limitations of viral-based gene therapy. The company's therapy uses synthetic biology and engineered gene circuits to make covalently closed and circular deoxyribonucleic acid molecules, providing healthcare professionals with access to new gene therapies which safety issues, and technical obstacles have beset.

Replicate Bioscience

Series A in 2021
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

Replicate Bioscience

Funding Round in 2021
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

Aulos Bioscience

Series A in 2021
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

Intergalactic Therapeutics

Seed Round in 2021
Developer of a focal non-viral gene therapy designed to overcome the limitations of viral-based gene therapy. The company's therapy uses synthetic biology and engineered gene circuits to make covalently closed and circular deoxyribonucleic acid molecules, providing healthcare professionals with access to new gene therapies which safety issues, and technical obstacles have beset.

Nereid Therapeutics

Series A in 2020
NEREID THERAPEUTICS INC. focuses in the discovery of small molecules that can modulate protein interactions found in disease states using liquid-liquid phase separation. The company is based in Cambridge, Massachusetts.

Nine Square Therapeutics

Series A in 2020
Nine Square Therapeutics is discovering new small-molecule therapeutics for degenerative movement disorders including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative disorders such as essential tremor and dyskinesias, by integrating computational chemistry, biophysics, and computational biology into machine-learning-enabled cell profiling platforms for target identification, chemical optimization, and patient stratification. It was founded in 2020 and headquartered in New York, United States.

Limelight Bio

Venture Round in 2019
Limelight Bio is a multi-platform, multi-disease focused biopharmaceutical company expanding the limits of gene therapy. The company is developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors to enable the treatment of debilitating inherited diseases that cannot be addressed by current technologies; such as those caused by mutations in large genes and autosomal dominant inheritance patterns. Limelight Bio's proprietary technologies are designed to overcome limitations of currently available viral-based treatments to address a wider range of diseases. It was founded in 2016 and is headquartered in Philadelphia, Pennsylvania, United States.

Gala Therapeutics

Venture Round in 2019
Gala Therapeutics is a privately-held medical device company based in Menlo Park, California, focused on developing disease-modifying therapies for patients with lung cancer, chronic obstructive pulmonary disease (COPD), asthma, and other pulmonary diseases. Founded in 2015, the company aims to enhance survival rates and improve the quality of life for patients. Its innovative therapies cater to the needs of interventional pulmonologists, thoracic surgeons, and other healthcare professionals, enabling them to deliver more effective treatments and achieve better medical outcomes for those suffering from pulmonary conditions.

Chinook Therapeutics

Series A in 2019
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

Bellus Health

Post in 2018
Bellus Health Inc. is a clinical-stage biopharmaceutical company based in Laval, Canada, that focuses on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. The company is also engaged in developing KIACTA™, a treatment for AA amyloidosis, a rare kidney disease, which has completed its Phase 3 study. KIACTA™ is also being explored for sarcoidosis, a serious inflammatory condition affecting the lungs. Additionally, Bellus Health is working on Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies underway. The company has a pipeline that includes research on AL amyloidosis, where amyloid protein accumulation leads to organ dysfunction.

Stoke Therapeutics

Series B in 2018
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Akero Therapeutics

Series A in 2018
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.

Corvidia

Series B in 2018
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.

Braeburn

Debt Financing in 2018
Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are dedicated to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers, and society.

Stoke Therapeutics

Series A in 2018
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Elstar Therapeutics

Series A in 2018
Elstar Therapeutics Inc. operates as a biotechnology company that develops immunotherapies. The company produces molecules that treat various diseases in oncology and autoimmunity. Elstar Therapeutics Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Syntimmune

Series B in 2017
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for various autoimmune diseases. Established in 2013 by Laurence and Richard Blumberg, Syntimmune aims to advance novel therapies by leveraging its expertise in the biology of the neonatal Fc receptor (FcRn), which plays a critical role in the pathogenesis of IgG-mediated autoimmune conditions. The company is committed to addressing unmet medical needs in this therapeutic area. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals.

Syntimmune

Series A in 2016
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for various autoimmune diseases. Established in 2013 by Laurence and Richard Blumberg, Syntimmune aims to advance novel therapies by leveraging its expertise in the biology of the neonatal Fc receptor (FcRn), which plays a critical role in the pathogenesis of IgG-mediated autoimmune conditions. The company is committed to addressing unmet medical needs in this therapeutic area. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals.

Rox Medical

Series E in 2016
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

VytronUS

Series C in 2016
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.

Syntimmune

Series A in 2016
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for various autoimmune diseases. Established in 2013 by Laurence and Richard Blumberg, Syntimmune aims to advance novel therapies by leveraging its expertise in the biology of the neonatal Fc receptor (FcRn), which plays a critical role in the pathogenesis of IgG-mediated autoimmune conditions. The company is committed to addressing unmet medical needs in this therapeutic area. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals.

Corvidia

Series A in 2016
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.

QualDerm Partners

Venture Round in 2016
QualDerm Partners provides strategic leadership and practice management services for dermatologists and skin care professionals across the southeastern United States, enabling them to focus more on patients and less on administrative efforts. They foster a practice-centric philosophy, which defines the culture that drives how they manage our business to provide the best care for the patients they serve.

Cure Forward

Venture Round in 2015
Cure Forward is a healthcare company based in Boston, Massachusetts, that focuses on genomic medicine and oncology. Founded in 2014, it operates an online portal designed to provide patients and physicians with access to genomic testing data. This platform enables users to explore and identify advanced treatment options, particularly for cancer patients. By facilitating communication and information sharing between patients and healthcare providers, Cure Forward aims to enhance the decision-making process in clinical trials and treatment selection.

VytronUS

Series B in 2014
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.

Aileron Therapeutics

Series E in 2014
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Syntimmune

Series A in 2014
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for various autoimmune diseases. Established in 2013 by Laurence and Richard Blumberg, Syntimmune aims to advance novel therapies by leveraging its expertise in the biology of the neonatal Fc receptor (FcRn), which plays a critical role in the pathogenesis of IgG-mediated autoimmune conditions. The company is committed to addressing unmet medical needs in this therapeutic area. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals.

Dermira

Series C in 2014
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.

Cerecor

Series B in 2014
Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases, with a particular focus on inherited metabolic disorders. The company's pipeline includes therapies such as CERC-801, CERC-802, and CERC-803, which have completed phase I clinical trials. Additionally, Cerecor is developing CERC-007, an anti-IL-18 monoclonal antibody for autoimmune inflammatory diseases, and CERC-006, a dual mTOR inhibitor for complex lymphatic malformations. Other notable developments include CERC-002 for pediatric-onset Crohn's disease, CERC-913 for mitochondrial disorders, and CERC-005 for rare auto-inflammatory diseases. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions. Founded in 2011 and headquartered in Rockville, Maryland, the company was previously known as Ceregen Corporation before rebranding in March 2011.

Tendyne Holdings

Series C in 2014
Tendyne Holdings Inc. develops medical device for transcatheter mitral valve replacement, repair, and targeting mitral regurgitation. The company was incorporated in 2010 and is based in Roseville, Minnesota. As of August 2015, Tendyne Holdings Inc. operates as a subsidiary of Abbott Laboratories.
Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.

Aileron Therapeutics

Series E in 2013
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Eledon Pharmaceuticals

Series E in 2013
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.

Aileron Therapeutics

Series D in 2013
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Eledon Pharmaceuticals

Series D in 2011
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.

Aileron Therapeutics

Series D in 2009
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Eledon Pharmaceuticals

Series D in 2009
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.

Aileron Therapeutics

Series C in 2008
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Eledon Pharmaceuticals

Series B in 2007
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.

Aileron Therapeutics

Series B in 2007
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Aileron Therapeutics

Series A in 2006
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.

Cyrano Sciences

Venture Round in 2000
Cyrano Sciences, is focused on providing chemical and biological sensors and software solutions.